Zymeworks Inc. (ZYME) Stock Price

ZYMEStock

$27.47+90.53%52W

Market Cap$1.96B

P/E—

PEG Ratio—

Div yield—

Beta1.15

ZYME Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)14.33%

Price vs S&P 500 (4W)24.19%

VGM Score50.22

Book Value / Share (Quarterly)$2.22

P/TBV (Annual)7.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-36.43%

Cash Flow / Share (Quarterly)$-1.05

Price vs S&P 500 (YTD)-2.69%

Net Profit Margin (TTM)-126.33%

EPS (TTM)$-1.37

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-1.37

Revenue Growth (5Y)22.13%

EPS (Annual)$-1.08

ROI (Annual)-30.22%

Net Profit Margin (5Y Avg)-231.32%

Cash / Share (Quarterly)$4.95

Revenue Growth QoQ (YoY)-91.90%

ROA (Last FY)-23.41%

Revenue Growth TTM (YoY)3.34%

EBITD / Share (TTM)$-1.46

ROE (5Y Avg)-30.36%

Operating Margin (TTM)-140.35%

Cash Flow / Share (Annual)$-0.47

P/B Ratio10.93x

P/B Ratio (Quarterly)11.29x

Net Income / Employee (Annual)$-307,300

EV / Revenue (TTM)22.02x

Net Interest Coverage (TTM)-96.25x

ROA (TTM)-25.19%

EV / EBITDA (TTM)8.45x

EPS Incl Extra (Annual)$-1.08

Current Ratio (Annual)5.88x

Quick Ratio (Quarterly)10.36x

3-Month Avg Trading Volume0.61M

52-Week Price Return90.53%

EV / Free Cash Flow (Annual)0.77x

Revenue / Employee (TTM)$307,800

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)16.87x

Asset Turnover (Annual)0.31x

52-Week High$29.75

Operating Margin (5Y Avg)-244.90%

EPS Excl Extra (Annual)$-1.08

CapEx CAGR (5Y)-17.89%

Tangible BV CAGR (5Y)-7.14%

26-Week Price Return25.58%

Quick Ratio (Annual)5.52x

13-Week Price Return14.58%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.82x

Enterprise Value$1.79B

Revenue / Share Growth (5Y)12.68%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)-16.71%

Revenue / Employee (Annual)$401,400

Pretax Margin (Annual)-75.26%

Cash / Share (Annual)$3.04

3-Month Return Std Dev43.44%

Net Income / Employee (TTM)$-388,800

ROE (Last FY)-30.22%

Net Interest Coverage (Annual)-726.00x

EPS Basic Excl Extra (Annual)$-1.08

P/FCF (TTM)159.75x

Receivables Turnover (TTM)5.55x

EV / Free Cash Flow (TTM)1.36x

Total Debt / Equity (Quarterly)1.51x

EPS Incl Extra (TTM)$-1.37

Receivables Turnover (Annual)3.51x

ROI (TTM)-30.80%

P/S Ratio (TTM)22.00x

Pretax Margin (5Y Avg)-229.54%

Revenue / Share (Annual)$1.41

Tangible BV / Share (Annual)$3.55

Forward P/E31.73x

Price vs S&P 500 (52W)72.22%

Year-to-Date Return9.27%

5-Day Price Return10.36%

EPS Normalized (Annual)$-1.08

ROA (5Y Avg)-21.12%

Net Profit Margin (Annual)-76.56%

Month-to-Date Return31.13%

Cash Flow / Share (TTM)$3.17

EBITD / Share (Annual)$-1.18

Operating Margin (Annual)-87.34%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-30.35%

LT Debt / Equity (Quarterly)1.51x

EPS Basic Excl Extra (TTM)$-1.37

P/TBV (Quarterly)11.37x

P/B Ratio (Annual)7.39x

Pretax Margin (TTM)-127.94%

Book Value / Share (Annual)$3.57

Price vs S&P 500 (13W)11.78%

Beta1.15x

P/FCF (Annual)13.64x

Revenue / Share (TTM)$1.09

ROE (TTM)-37.79%

52-Week Low$13.60

vGradeD

gGradeC

mGradeB

vgmGradeC

ZYME Earnings Surprise History

Q2 250.03est. -0.47

Q3 25-0.26est. -0.32

Q4 25-0.55est. -0.32

Q1 26-0.59est. -0.10

Q2 26-0.62est. -0.59

ZYME Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.28

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ZYMEZymeworks Inc.	D	C	B	$27.47
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics using its proprietary drug development platform. Its lead candidate, zanidatamab, is a HER2-targeted bispecific antibody currently in Phase 1/2 and pivotal clinical trials for solid tumors expressing HER2. The company also maintains a preclinical pipeline in oncology and other therapeutic areas.